Adamis Pharmaceuticals Corporation(ADMP)

Description: Adamis Pharmaceuticals Corporation, a biopharmaceutical company, engages in the development and commercialization of specialty pharmaceutical products in the therapeutic areas of oncology, immunology and infectious diseases, and allergy and respiratory. The company focuses on the development of small molecule compounds, which comprise APC-100, APC-200, and APC-300 for the treatment of human prostate cancer; telomerase vaccine technologies; and other vaccine technologies for providing protection against various viral infectious agents. Its products under development also comprise TeloB-VAX, a novel cell-based vaccine product for prostate cancer; and Savvy(C31G), a contraceptive gel. The company's allergy and respiratory product pipeline includes Epinephrine Injection USP 1, a pre-filled single dose syringe product for use in the emergency treatment of extreme acute allergic reactions or anaphylactic shock; APC-1000, a steroid hydrofluoroalkane (HFA) metered dose inhaler product for asthma and chronic obstructive pulmonary disease; APC-2000, a generic HFA bronchodilator; and APC-3000, an HFA pressurized metered dose nasal steroid for the treatment of seasonal and perennial allergic rhinitis. It has a strategic manufacturing, supply, and product development agreement with Beximco Pharmaceuticals Ltd. The company is based in San Diego, California.

---

Keywords: Medicine Biopharmaceutical Pharmaceutical Products Infectious Diseases Immunology Prostate Cancer Allergy Asthma Respiratory Therapy Chronic Obstructive Pulmonary Disease Syringe Smoking Cessation Pulmonary Disease Rhinitis Inhaler Metered Dose Inhaler Epinephrine Infectious Agents Telomerase Emergency Treatment Anaphylactic Shock Bronchodilator Perennial Allergic Rhinitis

---

Home Page: www.adamispharmaceuticals.com

ADMP Technical Analysis

11682 El Camino Real
San Diego, CA 92130
United States
Phone: 858 997 2400

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)